Company Encyclopedia
View More
name
JINLING PHARM.
000919.SZ
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products and medical devices in China. The company provides Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, polyarteritis, acute arterial embolism of extremities, diabetic gangrene, intravenous thrombus, thrombophlebitis, etc.; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia; lentinan injection for the treatment of malignant tumors; and absorbable gelatin sponges for the treatment of wound hemostasis. It also offers medical and health care services. Jinling Pharmaceutical Company Limited was founded in 1998 and is headquartered in Nanjing, China.
3.159 T
000919.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking155/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE0.85%D
    • Profit Margin1.03%C
    • Gross Margin23.15%D
  • Growth ScoreD
    • Revenue YoY-13.52%E
    • Net Profit YoY-62.37%D
    • Total Assets YoY12.48%B
    • Net Assets YoY9.23%B
  • Cash ScoreC
    • Cash Flow Margin9750.34%A
    • OCF YoY-13.52%E
  • Operating ScoreC
    • Turnover0.55C
  • Debt ScoreA
    • Gearing Ratio19.54%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    JINLING PHARM.: Net profit in the third quarter was 20.1248 million yuan, a year-on-year decrease of 1.84%

    JINLING PHARM. announced that its revenue for the third quarter was 779 million yuan, a year-on-year decrease of 4.53%; net profit was 20.1248 million yuan, a year-on-year decrease of 1.84%. Revenue for the first three quarters was 2.38 billion yuan, a year-on-year decrease of 5.95%; net profit was 68.4583 million yuan, a year-on-year decrease of 10.81%

    Zhitong·
    SZ
    000919
    -0.14%
    Zhitong·
    SZ
    000919
    -0.14%

    JINLING PHARM.: Olaratumab tablets approved to conduct Phase III clinical research

    JINLING PHARM. announced that its subsidiary JINLING Pharmaceutical Factory has received approval from the National Medical Products Administration to conduct Phase III clinical research on Elagolix tablets. Elagolix tablets are a GnRH antagonist primarily used to treat moderate to severe pain associated with endometriosis. This drug has been included in the national "Second Batch of Encouraged Generic Drug List."

    Zhitong·
    SZ
    000919
    -0.14%
    Zhitong·
    SZ
    000919
    -0.14%

    JINLING PHARM.: The holding subsidiary has received approval for the listing of potassium sulfate

    JINLING PHARM.'s subsidiary Chizhou Dongsheng Pharmaceutical Co., Ltd. has been approved by the National Medical Products Administration to list potassium sulfate, meeting domestic drug registration requirements, and can be produced and sold in the domestic market. This will enrich the company's active pharmaceutical ingredient product line, but will have little impact on the company's performance in the short term

    Zhitong·
    SZ
    000919
    -0.14%
    Zhitong·
    SZ
    000919
    -0.14%

    JINLING PHARM.: Fuzhou Meifeng Pharmaceutical Factory's hydrolyzed protein injection has received re-registration approval

    JINLING PHARM.'s Fuzhou Meifeng Pharmaceutical Factory has received approval from the Fujian Provincial Drug Administration for the re-registration of hydrolyzed protein injection. The specification of this drug is 500ml:25g, mainly used for severe amino acid deficiency and hypoproteinemia. Although the approval helps restore production and sales, the recent performance impact is minimal, and market and policy factors bring uncertainty, reminding investors to pay attention to risks

    Zhitong·
    SZ
    000919
    -0.14%
    Zhitong·
    SZ
    000919
    -0.14%

    JINLING PHARM. branch received the acceptance notice for Olaratumab tablets

    JINLING PHARM.'s subsidiary Nanjing JINLING Pharmaceutical Factory recently received the acceptance notice from the National Medical Products Administration for the application of domestic production drug registration clinical trials for Elagolix tablets. Elagolix is a GnRH antagonist that was approved by the FDA in 2018, specifically for the treatment of moderate to severe pain associated with endometriosis. If the clinical trials go smoothly, it will enhance the company's product line and competitiveness

    Zhitong·
    SZ
    000919
    -0.14%
    Zhitong·
    SZ
    000919
    -0.14%
    © 2025 Longbridge｜Disclaimer